Open-Label, Single-Arm, Phase 3b, Multi-Centre Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) Including Those With the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment With a B-Cell Receptor Inhibitor
The purpose of this open-label, single-arm study is to evaluate the efficacy of venetoclax
monotherapy in approximately 250 participants with relapsed/refractory CLL including those
with the 17p deletion or TP53 mutation (assessed by local lab) OR those who have received
prior treatment with a B-cell receptor inhibitor. The starting dose of venetoclax is 20 mg
once daily. The dose must be gradually increased over a period of 5 weeks up to the daily
dose of 400 mg. Participants may continue receiving venetoclax for up to 2 years. After the
treatment period, participants may continue on into a 2-year follow-up period.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society